Search
Home
Products
GSK429286A
GSK429286A WeChat WhatsApp
Product Name GSK429286A
Price: Inquiry
Catalog No.: CN00184
CAS No.: 864082-47-3
Molecular Formula: C21H16F4N4O2
Molecular Weight: 432.37 g/mol
Purity: >=98%
Type of Compound: Alkaloids
Physical Desc.: Powder
Source:
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
SMILES: O=C1NC(=C(C(C1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F)C
Contact us
First Name:
Last Name:
E-mail:
Question:
Description GSK429286A is a selective inhibitor of ROCK1 with an IC50 value of 14 nM.
Target ROCK1:14 nM (IC50) RSK:780 nM (IC50) p70S6K:1940 nM (IC50)
In Vitro GSK429286A at 1 μM reduces ROCK2 activity over 20-fold, under conditions in which the only other kinase tested that is significantly inhibited is MSK1 whose activity is reduced ~5-fold. GSK429286A is a more selective ROCK2 inhibitor than the widely utilized ROCK inhibitor Y-27632 as assessed on kinase-specificity panel, and does not significantly inhibit LRRK2 even at doses as high as 30 μM (500-fold higher than IC50 of inhibition of ROCK2). GSK429286A slightly inhibits RSK and p70S6K with IC50 of 0.78 μM and 1.94 μM, respectively. GSK429286A significantly inhibits rat aortic ring dilation with IC50 of 190 nM[2].
In Vivo GSK429286A has 61% oral bioavailability in male Sprague-Dawley rats. Oral administration of GSK429286A at single doses of 3-30 mg/kg dramatically reduces mean arterial pressure in the spontaneously hypertensive rats (SHRs) in a dose-dependent manner, with a maximum decrease of 50 mmHg after approximately 2 hours treatment at dose of 30 mg/kg[1].
Animal Admin Rats: Spontaneously hypertensive rats (SHRs) are treated with GSK429286A to establish its effect on mean arterial pressure. Compound is administered by single dose oral gavage (3, 10, 30 mg/kg)[1].
Density1.5±0.1 g/cm3
Boiling Point688.4±55.0 °C at 760 mmHg
Flash Point370.2±31.5 °C
Exact Mass432.120941
PSA90.37000
LogP3.97
Vapour Pressure0.0±2.1 mmHg at 25°C
Storage condition2-8°C